Most Common Primary Bone Cancer
- Distal Femur: Most common location (50%), then proximal tibia (25%).
- Bimodal Age: Adolescents (primary) and over 60 (secondary - Paget's).
- Sunburst: Spiculated periosteal reaction - the most characteristic sign, but NOT pathognomonic (see Ewing, neuroblastoma metastases, aggressive infection).
- Codman Triangle: Elevated periosteum at tumour margin.
- MAP Protocol: Methotrexate (high-dose), Adriamycin, cisPlatin.
- Histologic Response: Over 90% necrosis = good prognosis (75-80% survival) - prognostic only; a poor response does NOT change the drugs.
- “Distal femur most common primary bone cancer location
- “Sunburst + Codman triangle = osteosarcoma until proven otherwise
- “Neoadjuvant chemo BEFORE surgery - treats micrometastases
- “Over 90% necrosis = good response and better prognosis
- “Biopsy tract must be excised with specimen - plan with surgeon
Overview/Epidemiology
Osteosarcoma is the most common primary malignant bone tumour, defined by the direct formation of osteoid or immature bone by malignant mesenchymal cells. It is the most common primary bone cancer in adolescents, with an incidence of 3-4 per million per year, about 400 new cases a year in the USA, and a male to female ratio of 1.5:1.
Who. The age distribution is bimodal. The primary peak, at 10-20 years, falls in the years of rapid skeletal growth, and its tumours are metaphyseal and of the conventional type. The secondary peak, over 60, is Paget's sarcoma: axial, and with a poor prognosis.
Paget's sarcoma. Secondary osteosarcoma develops in 1% of patients with Paget's disease. Suspect it when known Paget's brings a sudden increase in pain, rapid enlargement or a rising alkaline phosphatase. The prognosis is very poor, with 5-year survival under 10%.
Risk factors. The recognised associations are listed below; the germline syndromes and radiation-induced disease have their own sections after the evidence.
- Prior radiation therapy
- Paget's disease
- Li-Fraumeni syndrome (p53)
- Hereditary retinoblastoma (RB1)
- Rothmund-Thomson syndrome
Where. The tumour has a metaphyseal predilection and is typically found around the knee. Flat bones, the pelvis and skull, are sites in older patients.
- Distal femur 50%
- Proximal tibia 25%
- Proximal humerus 10%
- Other long bones 15%
Anatomy/Biomechanics
Why the metaphysis. Osteosarcoma arises from primitive mesenchymal bone-forming cells, and the metaphyses have the highest osteoblastic activity during growth. Their rich blood supply facilitates tumour growth. The growth plate initially acts as a barrier to epiphyseal extension, though a less effective one than was previously thought.
How it spreads. The tumour extends in several directions, each against a different barrier:
- Barrier
- Cortical bone
- Clinical Significance
- Skip lesions possible
- Barrier
- Soft tissue planes
- Clinical Significance
- Neurovascular involvement risk
- Barrier
- Joint capsule
- Clinical Significance
- Rare, but indicates Stage IIB/III
Distal femur. The popliteal artery and vein lie posterior to the femur and are at risk with posterior extension. The femoral vessels run in Hunter's canal, a consideration for an anterior or medial approach, and the sciatic nerve lies posterolaterally, dividing into the tibial and common peroneal nerves above the knee.
Proximal tibia. The popliteal vessels lie posteriorly and trifurcate below the knee, and the anterior tibial vessels pass through the interosseous membrane. The common peroneal nerve wraps around the fibular neck and is at high risk.
Classification Systems
The WHO classification sorts osteosarcoma by grade and by where it sits in the bone, and the table below carries the chemotherapy decision for each subtype. Staging uses two systems: Enneking for surgical planning and AJCC for documentation and prognostication.
Conventional osteosarcoma, three-quarters of cases, is high grade and intramedullary and requires the full chemotherapy protocol. The surface tumours differ in grade, and the low-grade parosteal type is the one that needs no chemotherapy.
- Grade
- High
- Location
- Intramedullary
- Chemotherapy
- Yes - MAP protocol
- Grade
- High
- Location
- Intramedullary
- Chemotherapy
- Yes - Same as conventional
- Grade
- High
- Location
- Intramedullary
- Chemotherapy
- Yes - May add Ewing's protocol
- Grade
- Low
- Location
- Surface (posterior femur)
- Chemotherapy
- No - Wide resection only
- Grade
- Intermediate
- Location
- Surface (diaphysis)
- Chemotherapy
- Consider, neoadjuvant and adjuvant - case-by-case decision
- Grade
- High
- Location
- Surface
- Chemotherapy
- Yes - Full protocol
Clinical Presentation
The classic triad is pain, a mass and restricted range of motion, and a history of under 6 months is typical.
Pain. Pain is progressive and worse at night. It is initially activity-related, then becomes constant and may wake the patient from sleep; NSAIDs initially help.
The mass. A swelling develops over weeks to months. It is firm, fixed to bone and may be warm to touch; skin changes are rare and late, and visible deformity is late.
Red flags. Pathological fracture, respiratory symptoms from metastases, weight loss (late) and night sweats (rare).
Examination. Look at the site of the swelling, for wasting of adjacent muscle, and at limb length if the growth plate is involved. The mass is firm, fixed to bone and tender, and may be warm from increased vascularity; range of motion is reduced if it lies near a joint. Lymph nodes are rarely involved (under 3%). Pulses are rarely compromised and sensory change is late, but record motor function and compartment tension.
10% of osteosarcomas present with a pathological fracture. It does NOT automatically preclude limb salvage, and with careful planning survival is similar, but the fracture haematoma is contaminated, which makes the surgery harder, and chemotherapy timing may need to be modified. Pathological fractures historically worsened prognosis because of tumour contamination; modern neoadjuvant chemotherapy and surgical techniques have improved outcomes. The limb is immobilised until surgery, and the fracture site must be included in the resection specimen.
Differential diagnosis.
- Key Distinguishing Features
- Diaphyseal, permeative, onion-skin periosteal, smaller cell
- Key Distinguishing Features
- Older patients (40-60), axial, chondroid matrix (arcs/rings)
- Key Distinguishing Features
- Epiphyseal, eccentrically lytic, no matrix
- Key Distinguishing Features
- Systemic symptoms, sequestrum, involucrum
- Key Distinguishing Features
- Transverse, no soft tissue mass, healing callus
- Key Distinguishing Features
- Eccentric, expansile, fluid levels on MRI
Investigations
Radiographs are the first-line investigation. The lesion is usually metaphyseal, eccentric or central, and aggressive: permeative or moth-eaten, with a wide zone of transition, cortical destruction and an extraosseous soft tissue mass that may show calcification. Together these make the classic "aggressive bone lesion".
The matrix. Osteoid production gives a cloud-like density, the "cumulus cloud" appearance, with dense sclerotic areas in a mixed lytic and sclerotic lesion.
The periosteal reaction. The sunburst (spiculated) pattern is the most characteristic, but it is not pathognomonic: it is also seen in Ewing sarcoma, metastatic neuroblastoma and aggressive infection. The Codman triangle, periosteum elevated at the margin of the lesion, is again a marker of speed, not of cell type. Both indicate that the lesion is outgrowing the periosteum; it is the osteoid matrix, not the periosteal reaction, that points to osteosarcoma.
MRI is essential for surgical planning. Each sequence answers a different question:
- T1-weighted: tumour extent and marrow replacement (low signal)
- T2/STIR: oedema and soft tissue extent (high signal)
- Gadolinium: enhancement pattern and viable tumour
It must show the intramedullary extent, which sets the proximal resection level, together with any skip lesion, neurovascular involvement, joint involvement and the soft tissue extent.
Skip lesions occur in 1-5% of osteosarcomas. Always request MRI of the ENTIRE bone. Missing a skip lesion leads to inadequate resection and recurrence.
Staging the chest. Thin-cut (1-2mm) CT of the chest is essential. The lung is the most common site of metastasis, 80% of metastases, and pulmonary metastases are present at diagnosis in 15-20%.
Bone scan and PET-CT. A bone scan detects bone metastases and polyostotic disease, and the primary tumour shows hot uptake. PET-CT is increasingly used; it combines metabolic and anatomic data and is useful for response assessment. Complete staging is essential before treatment begins.
Blood tests. Alkaline phosphatase is elevated in 50% and is prognostic; an elevated LDH indicates a poor prognosis. A full blood count and renal and liver function give the baseline before chemotherapy.
Biopsy. The biopsy is the most important step in diagnosis, and it MUST be planned with the definitive surgeon. A wrong approach contaminates compartments, and violating these principles may necessitate amputation.
- Pros
- Less contamination, outpatient
- Cons
- May miss diagnosis (sampling)
- Indication
- Preferred in most centres
- Pros
- More tissue, higher accuracy
- Cons
- More contamination
- Indication
- If core non-diagnostic
- Pros
- Diagnostic + therapeutic
- Cons
- Contraindicated
- Indication
- Never for suspected osteosarcoma
Technique. The incision and tract follow these rules:
- Longitudinal incision along the planned resection
- Avoid contaminating neurovascular structures
- Through muscle (not between compartments)
- Meticulous haemostasis
- Mark the biopsy site for excision
Non-Operative Management
MAPMAP Chemotherapy
Hook:MAP your treatment - all 3 drugs needed for optimal survival.
Before surgery. Neoadjuvant chemotherapy runs for 8-12 weeks (2-4 cycles). Tumour shrinkage on imaging is not a reliable measure of response.
After surgery. Adjuvant chemotherapy adds a further 12-29 weeks, and the whole treatment takes approximately a year.
Toxicity. Methotrexate also causes hepatotoxicity and cisplatin neuropathy. Monitoring follows the drug: methotrexate levels and renal function, echo or MUGA for doxorubicin, creatinine and audiometry for cisplatin.
- Agent
- Doxorubicin
- Incidence
- 5-10%
- Prevention/Management
- Cumulative dose limit, serial echo
- Agent
- Cisplatin, MTX
- Incidence
- 10-20%
- Prevention/Management
- Hydration, dose adjustment
- Agent
- Cisplatin
- Incidence
- 10-30%
- Prevention/Management
- Audiometry, dose modification
- Agent
- MTX
- Incidence
- 40-60%
- Prevention/Management
- Leucovorin rescue, supportive care
- Agent
- All agents
- Incidence
- Universal
- Prevention/Management
- G-CSF, transfusions
- Agent
- All agents
- Incidence
- 2-5%
- Prevention/Management
- Long-term surveillance
Doxorubicin cardiotoxicity is cumulative and dose-dependent. The lifetime limit is typically 450mg/m², with echo or MUGA before each cycle; irreversible cardiomyopathy follows if it is exceeded.
Management Algorithm
Why chemotherapy. Surgery alone results in 80% recurrence, because micrometastases are present at presentation. Neoadjuvant chemotherapy shrinks the tumour, treats micrometastases and allows histologic assessment; adjuvant chemotherapy completes treatment and improves survival from 20% to 60-70%. The exception is parosteal osteosarcoma, treated by wide resection alone.
The sequence. Surgery is performed after neoadjuvant chemotherapy so that the histologic response can be assessed.
- Staging: MRI, CT chest, bone scan
- Neoadjuvant MAP chemotherapy for 8-12 weeks
- Restaging
- Wide resection, with or without reconstruction: limb salvage (80-90%) or amputation
- Histologic assessment: the percentage of tumour necrosis
- Adjuvant chemotherapy: standard MAP continues whatever the response (below)
Limb salvage or amputation. Neurovascular encasement that cannot be reconstructed is an absolute indication for amputation. The other factors weigh the balance:
- Limb Salvage
- Good response to chemo
- Amputation
- Poor response, progression
- Limb Salvage
- Not encased
- Amputation
- Encased, not reconstructable
- Limb Salvage
- Adequate coverage possible
- Amputation
- Massive soft tissue loss
- Limb Salvage
- Expected functional limb
- Amputation
- Non-functional limb
- Limb Salvage
- No active infection
- Amputation
- Severe infection
- Limb Salvage
- Accepts risks, compliant
- Amputation
- Non-compliant, prefers amputation
Histologic response. The necrosis in the resected specimen is the strongest prognostic factor for survival, and it is prognostic, not predictive. It tells you how this patient is likely to do; it does not tell you to do anything differently.
- Response
- Good
- Prognosis
- 75-80% 5-year survival
- Action
- Continue same protocol
- Response
- Poor
- Prognosis
- 50-55% 5-year survival
- Action
- Continue standard MAP - do NOT intensify
The Huvos system grades it:
- Grade I: little or no necrosis
- Grade II: 50-90% necrosis
- Grade III: over 90% necrosis
- Grade IV: 100% necrosis (complete response)
The poor responder. EURAMOS-1 randomised 618 poor responders to standard MAP or intensified MAPIE and found no improvement in event-free survival (HR 0.98), with substantially more toxicity: febrile neutropenia in 73% versus 50%. Identifying a poor responder therefore changes the conversation and the surveillance, not the drugs.
Surgical Technique
Margins. A wide margin takes a minimum of 1-2cm of bone beyond the tumour and a cuff of normal tissue that includes the reactive zone. The biopsy tract, excised with the specimen, and any skip lesion must be included in the resection. The controversies table below notes that the exact millimetre threshold is not fixed.
Modular metal replacement is the most common reconstruction and remains the gold standard for most limb salvage, used at the distal femur, proximal tibia and proximal humerus. It gives immediate stability, allows early mobilisation and weight-bearing, and has no donor site morbidity.
The costs. Mechanical failure (revision at 5-10 years), infection and aseptic loosening (rates under Complications), and a limited lifespan in a young patient.
Growing prostheses are for the skeletally immature. Non-invasive lengthening is available, but multiple lengthening procedures are required.
Amputation. The indications are those in the limb salvage table above, together with massive soft tissue involvement and a pathological fracture with contamination. The level follows the tumour:
- Above-knee for distal femoral tumours
- Hip disarticulation for the proximal femur
- Forequarter for the proximal humerus (rarely needed)
Survival is equal. Multiple studies confirm that limb salvage and amputation have equivalent oncologic outcomes when appropriate margins are achieved. Limb salvage is preferred when feasible because function is better (see the MSTS scores under Outcomes), although quality of life after amputation is reported as similar.
Complications
The chemotherapy toxicities are tabulated under Non-Operative Management and the allograft-specific complications under Surgical Technique.
Early surgical complications.
- Wound infection or dehiscence (10-15%)
- Flap necrosis
- Deep vein thrombosis
- Neurovascular injury
- Periprosthetic fracture
Late surgical complications.
- Aseptic loosening (30% at 10 years)
- Prosthesis failure or breakage
- Infection (5-15% lifetime)
- Leg length discrepancy
- Conversion to amputation (10-15%)
Local recurrence. Recurrence is re-staged, locally and systemically, and the prognosis is worse, 30-40% survival depending on resectability. Further resection is done if possible and amputation if there is no salvage option, with chemotherapy if it was not previously given. The risk factors:
- Inadequate margins
- Poor histologic response
- A missed skip lesion
- Pathological fracture
- Biopsy tract violation
Postoperative Care
The first week. ICU or HDU for 24-48 hours after major surgery, mechanical and chemical DVT prophylaxis, multimodal analgesia and limb elevation, with the skin flaps and drain output assessed.
Weeks 1-6. Physiotherapy for range of motion begins. Weight-bearing depends on the reconstruction: touch weight-bearing progressing after an endoprosthesis, protected weight-bearing for 6-12 weeks after an allograft. Watch the wound for infection and dehiscence. Chemotherapy resumes when the wound has healed, usually at week 3-4.
- Timeline
- 0-6 weeks
- Goals
- Wound healing, ROM
- Activities
- Bed exercises, transfer training
- Timeline
- 6-12 weeks
- Goals
- Strength, progressive WB
- Activities
- Gait training, strengthening
- Timeline
- 3-6 months
- Goals
- Full function
- Activities
- Sport-specific training
- Timeline
- Ongoing
- Goals
- Monitor function
- Activities
- Activity modification as needed
Surveillance. Chest imaging is the backbone of follow-up, alongside clinical review. Beyond 5 years, monitor for the late effects of chemotherapy; late recurrence is possible, though rare after 10 years.
- Clinical exam and chest X-ray
- Every 3 months
- CT chest
- Every 6 months
- Local imaging
- Every 6 months
- Clinical exam and chest X-ray
- Every 6 months
- CT chest
- Annual
- Local imaging
- -
- Clinical exam and chest X-ray
- Annual clinical and radiographic review
- CT chest
- -
- Local imaging
- -
Outcomes/Prognosis
Survival. Localised disease, the majority of presentations, has a 5-year survival of 60-70%; metastatic disease at diagnosis, 20-30%. The effect of histologic response on these figures is set out under Management Algorithm.
Prognostic factors. Histologic response is the strongest. A conventional subtype at an extremity site is favourable; the rest are in the table.
- Favourable
- Over 90% necrosis
- Unfavourable
- Under 90% necrosis
- Favourable
- Localised disease
- Unfavourable
- Metastatic at diagnosis
- Favourable
- Extremity
- Unfavourable
- Axial skeleton, pelvis
- Favourable
- Under 8cm
- Unfavourable
- Over 8cm, skip lesions
- Favourable
- Normal
- Unfavourable
- Elevated
- Favourable
- Wide/negative
- Unfavourable
- Marginal/positive
Function after limb salvage. The MSTS functional score is 70-85%. Most patients return to normal daily activities, competitive sport is limited or modified, and prosthesis revision is expected at 10-15 years.
Function after amputation. Prosthetic fitting takes place 2-3 months after surgery. An above-knee amputation scores 60-70% on the MSTS, with quality of life similar to limb salvage but a higher energy expenditure for walking.
Germline Predisposition Syndromes: the Genetics Behind Osteosarcoma
Li-Fraumeni, hereditary retinoblastoma and Rothmund-Thomson are the germline predisposition syndromes behind a proportion of osteosarcomas, and they change how you counsel a young patient and their family - a different question from the Paget-associated secondary disease.
- Li-Fraumeni syndrome (germline TP53). A loss-of-function germline mutation in the TP53 tumour-suppressor gives a very high lifetime cancer risk, with osteosarcoma one of the classic component tumours (alongside soft-tissue sarcoma, breast cancer, brain tumours, adrenocortical carcinoma and leukaemia). An osteosarcoma in a very young child, multifocal disease, or a strong family cancer history should prompt consideration of Li-Fraumeni, referral for genetic counselling and germline testing, and awareness of the lifelong multi-cancer surveillance these families need.
- Hereditary retinoblastoma (germline RB1). Survivors of bilateral (germline) retinoblastoma carry a markedly increased risk of second cancers, and osteosarcoma is the single most common second malignancy - both spontaneously and, importantly, within a prior radiotherapy field because the retinoblastoma-treatment RB1-deficient tissue is radiosensitive. A history of childhood retinoblastoma in an osteosarcoma patient is a major red flag.
- RecQ-helicase (DNA-repair) syndromes. Rothmund-Thomson syndrome (RECQL4), and to a lesser extent Bloom and Werner syndromes, are autosomal-recessive DNA-repair disorders with an increased osteosarcoma risk - typically presenting younger and sometimes multifocally.
- Why it matters clinically. Recognising a predisposition syndrome triggers germline testing and genetic counselling, changes surveillance (the patient and relatives are at risk of further cancers), and informs treatment caution - particularly minimising radiotherapy exposure in RB1 and DNA-repair-defective patients, who are prone to radiation-induced second tumours.
Q: Which inherited syndromes predispose to osteosarcoma? A: Li-Fraumeni (germline TP53) - osteosarcoma is a classic component tumour; hereditary (bilateral) retinoblastoma (germline RB1) - osteosarcoma is the commonest second malignancy, especially in a prior radiotherapy field; and the RecQ-helicase DNA-repair syndromes - Rothmund-Thomson (RECQL4), Bloom, Werner. A very young, multifocal, or strong-family-history osteosarcoma warrants germline testing and genetic counselling, and radiotherapy should be minimised in RB1/DNA-repair patients.
Radiation-Induced Osteosarcoma and the Cahan Criteria
- What it is. A secondary sarcoma arising in a previously irradiated field, usually years to decades after radiotherapy for a different (often childhood) cancer. Osteosarcoma is the most common radiation-induced bone sarcoma, and the risk is dose-dependent and higher in genetically susceptible patients (notably germline RB1 retinoblastoma survivors and DNA-repair syndromes).
- The Cahan criteria (how it is defined). A post-radiation sarcoma is classically diagnosed when: (1) the tumour arises within the prior radiation field; (2) there is a latency period (typically several years - often five or more); (3) the sarcoma is histologically proven and distinct from the original irradiated lesion; and (4) the irradiated tissue was normal, or a different tumour type, before radiotherapy.
- Why it matters. Radiation-induced osteosarcoma tends to occur at older ages and in axial or previously-irradiated sites, is often higher-stage at presentation, and carries a worse prognosis than conventional extremity osteosarcoma. The surgical principles are unchanged (wide resection, chemotherapy for high-grade disease), but re-irradiated, scarred, hypovascular tissue makes resection and reconstruction harder - and it reinforces the case for minimising and carefully planning radiotherapy in children, especially those with a genetic predisposition.
Q: How is radiation-induced osteosarcoma recognised? A: By the Cahan criteria - a histologically-proven sarcoma, distinct from the original lesion, arising within a prior radiation field after a latency period (often five or more years), in tissue that was normal or a different tumour before radiotherapy. Osteosarcoma is the commonest radiation-induced bone sarcoma, is more frequent in RB1 survivors and DNA-repair syndromes, presents at older ages/axial sites, and has a worse prognosis than conventional osteosarcoma.
Guidelines, Registries & Global Practice
Global Epidemiology
- Incidence approximately 3-4 per million per year worldwide, the most common primary bone sarcoma of childhood and adolescence
- Bimodal distribution: a dominant adolescent peak (skeletal growth spurt) and a smaller secondary peak over 60 (often Paget-associated or radiation-induced), the latter carrying a markedly worse prognosis
- Outcomes plateaued internationally since the 1980s: 60-70% 5-year survival for localised disease, 20-30% for metastatic disease at presentation, with no major survival gain from chemotherapy intensification (EURAMOS-1)
Major Guidelines Side by Side
- Core recommendations
- MAP backbone; wide resection with limb salvage where margins achievable; metastasectomy for resectable lung disease
- Core recommendations
- Treat in reference sarcoma centres; neoadjuvant MAP, surgery, response-adapted continuation; no benefit from adding ifosfamide/etoposide for poor responders
- Core recommendations
- Mandatory referral to a recognised bone-sarcoma centre before biopsy; biopsy by (or directed by) the operating surgeon
- Core recommendations
- Plan biopsy along the definitive incision; excise the biopsy tract en bloc with the specimen
Registry and Network Evidence
- Cooperative groups (COSS, COG, EOI, SSG) feeding the EURAMOS collaboration provide the strongest randomised evidence base
- Bone-tumour endoprosthesis outcome data are pooled through specialist-centre series (eg Birmingham/Royal Orthopaedic Hospital) rather than national joint registries, which exclude tumour implants
- International tumour banking and biobanking underpin ongoing molecular and trial work
High- vs Limited-Resource Practice Variation
- High-resource settings: centralised multidisciplinary sarcoma units, neoadjuvant MAP, limb salvage in 80-90%, growing/expandable endoprostheses for skeletally immature children
- Limited-resource settings: later presentation with larger tumours and higher rates of pathological fracture, limited access to high-dose methotrexate monitoring, higher reliance on amputation and on biologic reconstruction (allograft, recycled autograft) where implants are unaffordable
Universal principle: Osteosarcoma must be managed by a specialist multidisciplinary sarcoma team, and biopsy must be planned with the definitive surgeon. Referral BEFORE biopsy is the single most important system-level safeguard worldwide.
Related pages: Ewing Sarcoma for the other small-round-cell malignancy of the same age group, which shares the sunburst and Codman signs and is separated by matrix and molecular testing rather than by periosteal reaction; Chondrosarcoma for the matrix-producing sarcoma that is chemoresistant, so the treatment logic on this page does not transfer; Parosteal Osteosarcoma and Periosteal Osteosarcoma for the surface variants, whose grade and prognosis differ enough that neoadjuvant chemotherapy is not automatic; Paget's Sarcoma for the secondary osteosarcoma behind the second peak of the bimodal age curve; Osteoid Osteoma and Osteoblastoma for the benign bone-forming lesions this must be separated from; Describing a Bone Tumour Radiograph and Predicting Bone Tumour by Age for the systematic approach that reaches this diagnosis; Limb Salvage Surgery Principles for the reconstruction decisions the Simon and Wafa evidence above informs; and Metastatic Bone Disease for the commoner destructive lesion that must be excluded in the older patient.
Summary Points
High-Yield Take-Home Messages
- Osteosarcoma = Most common primary bone cancer in adolescents, defined by osteoid production
- Distal femur most common site (50%), "around the knee" in growing skeleton
- Sunburst + Codman triangle on X-ray = osteosarcoma until proven otherwise
- Biopsy MUST be planned with definitive surgeon - wrong approach contaminates compartments
- MRI entire bone - skip lesions occur in 1-5%, change surgical planning
- Neoadjuvant chemotherapy essential - MAP protocol (Methotrexate, Adriamycin, Platinum)
- Histologic response is strongest prognostic factor - over 90% necrosis = good response
- Limb salvage in 80-90% - equivalent survival to amputation
- Parosteal = exception - low-grade surface tumor, wide resection alone, no chemo
- Metastatic disease still aim for cure - complete resection of ALL disease improves survival
Controversies & Areas of Uncertainty
- Current position
- Standard postoperative MAP remains standard of care
- Why it remains unsettled
- EURAMOS-1 showed adding ifosfamide/etoposide (MAPIE) gave no survival benefit and more toxicity; no regimen has reliably rescued poor responders
- Current position
- Added to chemotherapy in some guidelines (eg EMA approval); not universally adopted (eg not FDA-approved)
- Why it remains unsettled
- INT-0133 reported a survival signal of borderline statistical interpretation; benefit and cost-effectiveness still debated
- Current position
- Negative margin with a cuff of normal tissue; exact millimetre threshold not fixed
- Why it remains unsettled
- Necrotic, chemotherapy-treated tumour blurs the reactive zone; response quality may matter more than absolute distance
- Current position
- No longer an absolute contraindication if good chemotherapy response and clear margins
- Why it remains unsettled
- Older data suggested higher local recurrence; modern series show comparable outcomes with careful selection
- Current position
- CT chest plus bone scan remain core; PET-CT increasingly used
- Why it remains unsettled
- PET-CT response (SUV change) is prognostic but has not replaced histologic necrosis as the reference standard
- Current position
- Regular chest imaging and local review for at least 5 years
- Why it remains unsettled
- Optimal frequency, modality (CXR vs CT) and radiation/cost trade-offs are not standardised internationally
MCQ Practice Points
Q: What is the most common site for osteosarcoma? A: Distal femur (50%), followed by proximal tibia (25%), proximal humerus (10%). Remember: "Around the knee" in adolescents.
Q: What are the characteristic radiographic features of osteosarcoma, and are they pathognomonic? A: Sunburst periosteal reaction and Codman triangle, with permeative destruction, cloud-like osteoid matrix and a soft tissue mass. They are not pathognomonic - both signs simply report an aggressive periosteal reaction outrunning the periosteum, and either can appear in Ewing sarcoma, in metastatic neuroblastoma, in aggressive osteomyelitis and in subperiosteal haematoma. What points to osteosarcoma is the combination: an aggressive periosteal reaction plus mineralised osteoid matrix in a metaphysis around the knee in the second decade. The correct exam formulation is the one this page uses elsewhere - sunburst plus Codman triangle means osteosarcoma until proven otherwise, and the proof is the biopsy.
Q: What is the standard chemotherapy regimen for osteosarcoma? A: MAP - high-dose Methotrexate (with leucovorin rescue), Adriamycin (doxorubicin), cisPlatin.
Q: What defines a good histologic response in osteosarcoma? A: Over 90% tumor necrosis in resected specimen. This is the strongest prognostic factor (5-year survival 75-80% vs 50-55% for poor response).
Q: Which osteosarcoma subtype does NOT require chemotherapy? A: Parosteal osteosarcoma - low-grade surface tumor treated with wide resection alone. 90-95% 5-year survival. Watch for dedifferentiation.
Common MCQ Scenarios
- Key Answer Point
- Osteosarcoma - biopsy with surgeon
- Key Answer Point
- Parosteal osteosarcoma - no chemo
- Key Answer Point
- Continue standard adjuvant chemo
- Key Answer Point
- Include in resection, not contraindication to limb salvage
- Key Answer Point
- Still attempt limb salvage with modified approach
- Key Answer Point
- Poor prognostic factor
- Key Answer Point
- Suspect secondary osteosarcoma
Self-Assessment Quiz
Viva Scenarios
Practise clinical reasoning and management decisions out loud
“A 14-year-old boy presents with 3 months of worsening right knee pain. X-ray shows an aggressive metaphyseal lesion in the distal femur with a sunburst periosteal reaction and Codman triangle. How do you manage this patient?”
“A 35-year-old woman has a slowly enlarging mass on the posterior aspect of her distal femur for 2 years. X-ray shows a densely ossified surface lesion attached to the posterior cortex. Biopsy confirms low-grade parosteal osteosarcoma. How does management differ from conventional osteosarcoma?”
“A 16-year-old presents with a distal femur osteosarcoma. Staging CT chest reveals 3 pulmonary nodules consistent with metastatic disease. How does this change your management approach?”
CLINICAL FEATURES
- Distal femur most common (50%)
- Bimodal: adolescents + over 60 (Paget's)
- Sunburst + Codman triangle on X-ray
- Pain worse at night, progressive swelling
STAGING WORKUP
- MRI entire bone (skip lesions)
- CT chest (lung mets - 80% of distant disease)
- Bone scan (systemic staging)
- Biopsy planned with definitive surgeon
TREATMENT PROTOCOL
- Neoadjuvant: MAP chemo 8-12 weeks
- Wide resection (limb salvage 80-90%)
- Assess histologic necrosis (over 90% = good)
- Adjuvant chemotherapy to complete
SUBTYPES
- Conventional (75%): High-grade, needs chemo
- Telangiectatic: Lytic, same treatment
- Parosteal: Low-grade, NO chemo needed
- Periosteal: Intermediate, consider chemo
PROGNOSIS
- Localized: 60-70% 5-year survival
- Metastatic: 20-30% survival
- Over 90% necrosis: 75-80% survival
- Under 90% necrosis: 50-55% survival
EXAM TRAPS
- Biopsy through wrong approach
- Surgery without chemotherapy
- Missing skip lesions (MRI entire bone)
- Giving chemo for parosteal type
Evidence Base
Rosen G et al - Preoperative chemotherapy (T10 protocol)
- 57 extremity osteosarcomas treated with preoperative high-dose methotrexate, doxorubicin and BCD
- Histologic response (over 90% necrosis) used to tailor postoperative chemotherapy
- Poor responders salvaged by switching regimen: 32 of 35 (91%) remained disease-free short-term
- Established neoadjuvant chemotherapy and histologic response as the modern treatment paradigm
EURAMOS-1 (Marina N et al) - MAPIE vs MAP for poor responders
- Largest osteosarcoma trial: 2260 registered, 618 poor responders randomised (MAP vs MAPIE)
- Adding ifosfamide and etoposide (MAPIE) did NOT improve event-free survival (HR 0.98)
- MAPIE increased grade 3-4 toxicity (febrile neutropenia, non-haematological events)
- Defines standard postoperative MAP as standard of care even for poor responders
Simon MA et al - Limb-salvage vs amputation, distal femur osteosarcoma
- Multi-institutional retrospective study of 227 distal femur osteosarcomas
- No difference in survival between limb-sparing surgery, above-knee amputation, or hip disarticulation (p=0.8)
- Local recurrence and metastasis rates comparable across groups
- Overall 5-year survival 55%; disease-free survival 42%
Bacci G et al - Serum alkaline phosphatase as a prognostic factor
- 560 extremity high-grade osteosarcomas treated with neoadjuvant chemotherapy at Rizzoli
- On multivariate analysis only two factors independently predicted event-free survival
- Pre-treatment serum alkaline phosphatase (p=0.002) and chemotherapy-induced necrosis (p=0.0001)
- 5-year event-free survival 60%, overall survival 68%
Mankin HJ et al - The hazards of biopsy, revisited (MSTS)
- Musculoskeletal Tumor Society survey of 597 sarcoma biopsies across 21 institutions
- Diagnostic error rate 17.8%; biopsy problems altered management in 19.3% of patients
- Errors and complications two to twelve times higher when biopsy done at referring (non-treatment) centre
- 18 patients underwent unnecessary amputation due to biopsy-related problems
Wafa H, Grimer R, Jeys L et al - Total humeral endoprosthesis
- 34 patients (15 osteosarcoma) after whole-bone resection and endoprosthetic reconstruction
- Cumulative 10-year implant survival 90% (Kaplan-Meier)
- Periprosthetic infection was the most common surgical complication
- Mean MSTS functional score 83% in disease survivors